ArticleFuture oncology (London, England)2022

Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.

Matthew R Smith et al.PubMed ↗Publisher ↗

No numbers read from the abstract.